CN Patent

CN1131033C — 麻醉制剂

Assigned to Darwin Discovery Ltd · Expires 2003-12-17 · 22y expired

What this patent protects

药物可接受的，针对脑脊液(CSF)是等比重或高比重并等渗的水溶液，其中含有1-烷基-N-(2，6-二甲基苯基)-2-哌啶甲酰胺麻醉剂如布比卡因或左旋布比卡因和糖。如果该麻醉剂不超过0.75%w/v，则存在盐或其它非糖物质。因此，该糖的量可以控制在低于不存在其它非糖时提供等渗性需要的量。

USPTO Abstract

药物可接受的，针对脑脊液(CSF)是等比重或高比重并等渗的水溶液，其中含有1-烷基-N-(2，6-二甲基苯基)-2-哌啶甲酰胺麻醉剂如布比卡因或左旋布比卡因和糖。如果该麻醉剂不超过0.75%w/v，则存在盐或其它非糖物质。因此，该糖的量可以控制在低于不存在其它非糖时提供等渗性需要的量。

Drugs covered by this patent

chloroprocaine-hydrochloride (CHLOROPROCAINE HYDROCHLORIDE)

Patent Metadata

Patent number: CN1131033C
Jurisdiction: CN
Classification: —
Expires: 2003-12-17
Drug substance claim: No
Drug product claim: No
Assignee: Darwin Discovery Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.